Law360 (November 21, 2006, 12:00 AM EST) -- A federal appeals court has given generic drug maker Impax Laboratories Inc. another chance to strike down a hotly contested patent for the Lou Gehrig's disease treatment held by rival Aventis Pharmaceuticals Inc.
With the ruling, issued Monday, the U.S. Court of Appeals for the Federal Circuit rejected a lower court’s decision that Impax failed to prove the Aventis patent was invalid due to anticipation.
Impax argued the Aventis patent shouldn't have been issued because previous research into the neuromuscular disorder had already covered the developments....
Federal Circuit Boosts Impax In Aventis Patent Suit
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
